WallStreetZenWallStreetZen

NASDAQ: INO
Inovio Pharmaceuticals Inc Stock

$9.02+0.86 (+10.54%)
Updated Feb 27, 2024
INO Price
$9.02
Fair Value Price
-$0.91
Market Cap
$205.19M
52 Week Low
$3.89
52 Week High
$16.20
P/E
-1.19x
P/B
1.49x
P/S
122.36x
PEG
N/A
Dividend Yield
N/A
Revenue
$854.03k
Earnings
-$164.58M
Gross Margin
100%
Operating Margin
-19,123.88%
Profit Margin
-19,270.7%
Debt to Equity
0.4
Operating Cash Flow
-$134M
Beta
0.62
Next Earnings
Mar 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A

INO Overview

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

INO ($9.02) is overvalued by 1,092.71% relative to our estimate of its Fair Value price of -$0.91 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
INO ($9.02) is not significantly undervalued (1,092.71%) relative to our estimate of its Fair Value price of -$0.91 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
INO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INO due diligence checks available for Premium users.

Be the first to know about important INO news, forecast changes, insider trades & much more!

INO News

Valuation

INO fair value

Fair Value of INO stock based on Discounted Cash Flow (DCF)
Price
$9.02
Fair Value
-$0.91
Undervalued by
1,092.71%
INO ($9.02) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INO ($9.02) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

INO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.19x
Industry
14.95x
Market
36.02x

INO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.49x
Industry
6.23x
INO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

INO's financial health

Profit margin

Revenue
$388.4k
Net Income
-$33.9M
Profit Margin
-8,734.8%
INO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
INO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$193.1M
Liabilities
$54.9M
Debt to equity
0.4
INO's short-term assets ($174.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INO's short-term assets ($174.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
INO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$29.1M
Investing
-$5.5M
Financing
$698.6k
INO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

INO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
INO$205.19M+10.54%-1.19x1.49x
DRTS$205.69M+0.51%N/A2.22x
OPT$206.13M+7.95%-1.37x-35.22x
SLDB$203.39M+6.11%-2.23x1.41x
ADVM$202.05M+2.56%-1.59x1.97x

Inovio Pharmaceuticals Stock FAQ

What is Inovio Pharmaceuticals's quote symbol?

(NASDAQ: INO) Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol INO. Inovio Pharmaceuticals stock quotes can also be displayed as NASDAQ: INO.

If you're new to stock investing, here's how to buy Inovio Pharmaceuticals stock.

What is the 52 week high and low for Inovio Pharmaceuticals (NASDAQ: INO)?

(NASDAQ: INO) Inovio Pharmaceuticals's 52-week high was $16.20, and its 52-week low was $3.89. It is currently -44.32% from its 52-week high and 132% from its 52-week low.

How much is Inovio Pharmaceuticals stock worth today?

(NASDAQ: INO) Inovio Pharmaceuticals currently has 22,748,869 outstanding shares. With Inovio Pharmaceuticals stock trading at $9.02 per share, the total value of Inovio Pharmaceuticals stock (market capitalization) is $205.19M.

Inovio Pharmaceuticals stock was originally listed at a price of $708.10 in Dec 8, 1998. If you had invested in Inovio Pharmaceuticals stock at $708.10, your return over the last 25 years would have been -98.73%, for an annualized return of -16.01% (not including any dividends or dividend reinvestments).

How much is Inovio Pharmaceuticals's stock price per share?

(NASDAQ: INO) Inovio Pharmaceuticals stock price per share is $9.02 today (as of Feb 27, 2024).

What is Inovio Pharmaceuticals's Market Cap?

(NASDAQ: INO) Inovio Pharmaceuticals's market cap is $205.19M, as of Feb 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Inovio Pharmaceuticals's market cap is calculated by multiplying INO's current stock price of $9.02 by INO's total outstanding shares of 22,748,869.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.